•			ROOM RPP:135FUS		SERIAL NO. 0	8/811,361		
INF	ORMATION DISCLOSUI	KE CJRATIC	APPLICANT(S): MOL	LY F. KULI	ESZ-MARTIN			
•	(Osc several sector i neces	62 • 1	11 1997 FILING DATE: 3-4-97		GROUP: 1806	-1642		
•		7	PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
SRZ	4,786,718	11/88	WEINBERG ET AL.	-	·			
						1 10		
					-0	3 7		
						1, 0, 0		
	,							

	,,,,,,,,,							
1	<u></u>	FORE	IGN PATENT DOCUMENTS	ece .		· · · · · · · · · · · · · · · · · · ·		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
8	WO-A-9213970	8/92						
7	EP-A-O-529160	3/93						
	PCT/US92/00878	1/92	PCT					
- 0								
,	OTHER DOC	UMENTS (I	ncluding Author, Title, Date, Per	tinent Page	es, Etc.)			
	Cruse et al., "I	lustrated D	Pictionary of Immunology,"	CRC Pr	ess, p. 280			
0	TZ No. Mr. die	D.C4 -1	(T. 1.) / FO D		. 11	A1.		
805	Kulesz-Martin, M. t al., "Endogenous Mouse p53 Protein Generated by Alternative Splicing," J. Cellular Biochemistry Supplement, Vol. 0, No. 18c, 2/13/94 -2/20/1994,							
P	p. 170							
EXAMINER	Elaver	<u>L</u>	DATE CONSIDERED	3/18	128			
considered. Incl	ude copy of this form with next com					nce and not		
Form PTO-A820 (also form PTO-1			Patent and Trademark Office * U.S. DE PAGE	PARTMENT OF 1 OF	6			

ATTY DOCKET NO. SERIAL NO. 08/811,361 RPP:135FUS APPLICANT(S): MOLLY F. KULESZ-MARTIN INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) GROUP: 1806 1642 FILING DATE: 3/4/97 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Wu, Y. et al., "Physiological Protein Variant of the Mouse p53 Tumor Suppressor Gene," Proc. of the American Assoc. for Cancer Research, Annual Mtg., Vol. 35, 4/10/94-4/13/94, p. 605 Bayle, J. et al., "The Carboxyl-Terminal Domain of the p53 Protein Regulates Sequence-Specific DNA Binding Through its Nonspecific Nucleic Acid Binding Activity," Proc. Nat. Acad. Sciences of USA, Vol. 92, No. 12, 1995, pp. 5729-5733 Wu, Y. et al., "Wild-Type Alternatively Spliced p53: Binding to DNA and Interaction with the Major p53 Protein in Vitro and in Cells," The EMBO Journal, Vol. 13, No. 20, 1994, pp. 4823-4830 Sevier et al., Clin. Chem, 27: pp. 1797-1806, 1981 Gupta et al., PNAS USA, 90: pp. 2817-2821, 1993 Arai, N. et al., "Immunology Distinct p53 Molecules Generated by Alternative Splicing," Mol. and Cell. Biol., 6, 1986, pp. 3232-3239 Balmain, A. et al., "Cloning and Characterization of the Abundant Cytoplasmic 7S RNA from Mouse Cells," Nucleic Acids Res. 10, 1982, pp. 4259-4277 Bargonetti, J. et al., "Site-Specific Binding of Wild-Type p53 to Cellular DNA is Inhibited by SV40 T Antigen and Mutant p53," Genes & Dev. 6, 1992, pp. 1886-1898 Bischoff, J.R. et al., "Human p53 Inhibits Growth in Schizosaccharomyces Pombe," Mol. and Cell. Biol. 12, 1992, pp. 1405-1411 Burns, P.A. et al., "Loss of Heterozygosity and Mutational Alterations of the p53 Gene in Skin Tumors of Interspecific Hybrid Mice," Oncogene 6, 1991, pp. 2363-2369 Crook, T. et al., "Modulation of Immortalizing Properties of Human Papillomavirus Type 16E7 by p53 Expression," J. Virol. 6, 1991, pp. 505-510 Davies, R. et al., "Antioxidants Can Delay Liver Cell Maturation Which in Turn Affects γ-Glutamyltranspeptidase Expression," Carcinogen. 14, 1993, pp. 47-52

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

DATE CONSIDERED

		. ATTY DOCKET NO. RPP:135FUS	SERIAL NO. 08/811,361				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT(S): MOLLY F. KULESZ-MARTIN					
•	,	FILING DATE: 3/4/97	GROUP: 1806-1642				
•	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent	Pages, Etc.)				
R.	Eliyahu, D. et al., "Meth A Fibros p53 Species," Oncogene 3, 1988, p		wo Transforming Mutant				
	Farmer, G. et al., "Wild-Type p53 pp. 83-86	Activates Transcription	in vitro," Nature 358, 1992,				
	Finlay, C.A. et al., "The p53 Proto Transformation," Cell 57, 1989, pp	•	a Supressor of				
	Fontoura, B.M.A. et al., "p53 is Covalently Linked to 5.8S rRNA," Mol. Cell. Biol. 12, 1992, pp. 5145-5151						
	Foord, O.S. et al., "A DNA Bindin Type p53 Protein," Nucleic Acids	-					
	Foulkes, N.S. et al., "More is Bette Cell 68, 1992, pp. 411-414	Foulkes, N.S. et al., "More is Better: Activators and Repressors from the Same Gene," Cell 68, 1992, pp. 411-414					
	Hainaut, P. et al., "Interaction of Heat-Shock Protein 70 with p53 Translated in vitro Evidence for Interaction with Dimeric p53 and for a Role in the Regulation of p53 Conformation," EMBO J. 11, 1992, pp. 3513-3520						
	Han, K. et al., "Altered Levels of During Mouse Epidermal Cell Care	Endogenous Retrovirus-	Like Sequence (VL30) RNA nogenesis 3, 1990,				
	Han, K. et al., "Altered Expression Murine Epithelial Cell Transforma						
	Han, K. et al., "Alternatively Spliced p53 RNA in Transformed and Normal Cells of Different Tissue Types," Nucleic Acids Res. 20(8), 1992, pp. 1979-1981						
	Hupp, T.R. et al., "Regulation of t 1992, pp. 875-886	he Specific DNA Bindir	ng Function of p53," Cell 71,				
V	Jenkins, J.R. et al., "Cellular Imm Transformation-Associated Phosph pp. 5609-5626	sins, J.R. et al., "Cellular Immortalization by a cDNA Clone Encoding the sformation-Associated Phosphoprotein p53," Nucleic Acids Res. 12, 1984, 1609-5626					
EXAMINER	Range	DATE CONSIDERED 3	3198				
considered. Incl	ude copy of this form with next communication to applicant.	ce with MPEP 609; Draw line through c	itation if not in conformance and not				
Form PTO-A820	F	atent and Trademark Office * U.S. DEPARTMET	VT OF COMMERCE				

(also form PTO-1449)

ATTY DOCKET NO. SERIAL NO. 08/811,361 RPP:135FUS APPLICANT(S): MOLLY F. KULESZ-MARTIN INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) GROUP: 1806 1642 FILING DATE: 3/4/97 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Kastan, M.B. et al., "Participation of p53 Protein in the Cellular Response to DNA Damage," Cancer Research 51, 1991, pp. 6304-6311 Kastan, M.B. et al., "A Mammalian Cell cycle Checkpoint Pathway Utilizing p53 and GADD45 is Defective in Ataxia-Telangiectasia," Cell 71, 1992, pp. 587-597 Kulesz-Martin, M. et al., "Mouse Cell Clones for Improved Quantitation of Carcinogen-Induced Altered Differentiation," Carcinogenisis 6, 1985, pp. 1245-1254 Kulesz-Martin, M. et al., "Retinoic Acid Enhancement of an Early Step in the Transformation of Mouse Epidermal Cells in vitro," Carcinogenesis 7, 1986, pp. 1425-1429 Kulesz-Martin, M. et al., "Pemphigoid, Pemphigus and Desmoplakin as Antigenic Markers of Differentiation in Normal and Tumorigenic Mouse Keratinocyte Lines," Cell Tissue Kinet. 22, 1989, pp. 279-290

Kulesz-Martin, M. et al., "Tumor Progression of Murine Epidermal Cells After Treatment In vitro with 12-0-Tetradecanoylphorbol-13-Acetate or Retinoic Acid," Cancer Research 51, 1991, pp. 4701-4706 Kulesz-Martin, M. et al. "Properties of Carcinogen Altered Mouse Epidermal Cells Resistant to Calcium-Induced Terminal Differentiation," Carcinogen 4, 1983, pp. 1367-1377 Lane, D.P., "p53, Guardian of the Genome," Nature 358, 1992, pp. 15-16 Milne, D.M. et al., "Mutation of the Casein Kinase II Phosphorylation Site Abolishes the Anti-Proliferative Activity of p53," Nucleic Acids Res. 20, 1992, pp. 5565-5570 Milner, J., "The Role of p53 in the Normal Control of Cell Proliferation," Current Opinion in Cell Biology 3, 1991, pp. 282-286 Milner, J., "Different Forms of p53 Detected by Monoclonal Antibodies in Non-Dividing and Dividing Lymphocytes," Nature 20, 1984, pp. 143-145 Milner, J. et al., "Cotranslation of Activated Mutant p53 with Wilde Type Drives the Wild-Type p53 Protein into the Mutant Conformation," Cell 65, 1991, pp. 765-774 DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY DOCKET NO. SERIAL NO. 08/811,361 RPP:135FUS APPLICANT(S): MOLLY F. KULESZ-MARTIN

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FILING DATE: 3/4/97 GROUP: 4806 1642

	FILING DATE: 3/4/97 GROUP: 4806 [642]							
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Momand, J. et al., "The mdm-2 Oncogene Product Forms a Complex With the p53							
9	Protein and Inhibits p53-Mediated Transactivation," Cell 69, 1992, pp. 1237-1245							
1	Nigro, J.M. et al., "Human p53 and CDC2Hs Genes Combine to Inhibit the Prolifer-							
	ation of Saccharomyces Cerevisiae," Mol. and Cell Biol. 12, 1992, pp. 1357-1365							
Oren, M. et al., "Molecular Cloning of a cDNA Specific for the Murine po								
	Tumor Antigen," Proc. Natl. Acad. Sci. USA, 80, 1983, pp. 56-59							
	Prives, C. et al., "The p53 Tumor Suppressor Protein: Meeting Review," Genes &							
	Dev. 7, 1993, pp. 529-534							
	Ro, Y.S. et al., "p53 Protein Expression in Benign and Malignant Skin Tumors,"							
	Br. J. Dermatol. 12, 1993, pp. 237-241							
	Ruggeri, B. et al., "Alterations of the p53 Tumor Supressor Gene During Mouse Skin							
	Tumor Progression," Cancer Research 51, 1991, pp. 6615-6621							
	Schneider, B.L. et al., "7,12-Dimethylbenz[∝]anthracene-Induced Mouse Keratinocyte Transformation Without Harvey ras Protooncogene Mutations," J. Invest. Dermatology, 101, 1993, pp. 595-599							
	Seto, E. et al., "Wild-Type p53 Binds to the TATA-Binding Protein and Represses							
	Transcription," Proc. Natl. Acad. Sci. 89, 1992, pp. 12028-12032							
	Soussi, T. et al., "Structural Aspects of the p53 Protein in Relation to Gene Evolution,"							
	Oncogene 5, 1990, p. 945-952							
	Stenger, J.E. et al., "Formation of Stable p53 Homotetramers and Multiples of							
	Tetramers," Mol. Carcinogen. 5, 1992, pp. 102-106							
	Stephen, C.W. et al., "Mutant Conformation of p53 Precise Epitope Mapping Using							
	a Filamentous Phage Epitope Library," J. Mol. Biol. 225, 1992, pp. 577-583							
	Sturzbecher, H.S. et al., "A C-Terminal ∞-Helix Plus Basic Region Motif is the Major							
4	Structural Determinant of p53 Tetramerization," Oncogene 7, 1992, pp. 1513-1523							
EXAMINER	DATE CONSIDERED 3/18/98							
EXAMINER: Initi considered. Include	al if reference conditions whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not copy of this form with next communication to applicant.							

Form PTO-A820

ATTY DOCKET NO. SERIAL NO. 08/811,361 RPP: 135FUS APPLICANT(S): MOLLY F. KULESZ-MARTIN INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) FILING DATE: 3/4/97 GROUP: 4806 1642 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Vogelstein, B., "A Deadly Inheritance," Nature 348, 1990, pp. 681-682 Vogelstein, B. et al., "p53 Function and Dysfunction," Cell 70, 1992, pp. 523-526 Wade-Evans, A. et al., "Precise Epitope Mapping of the Murine Transformation-Associated Protein," p53 EMBO J. 4, 1985, pp. 699-706 Weintraub, H. et al., "The MCK Enhancer Contains a p53 Responsive Element," Proc. Natl. Acad. Sci. 88, 1991, pp. 4570-4571 Wolf, D. et al., "Isolation of a Full-Length Mouse cDNA Clone Coding for an Immunologically Distinct p53 Molecule," Mol. and Cell Biol. 51, 1985, pp. 127-132 Wolf, D. et al., "Reconstitution of p53 Expression in a Nonproducer Ab-MuLV-Transformed Cell Line by Transfection of a Functional p53 Gene," Cell 38, 1984, pp. 119-126 Yewdell, J.W. et al., "Monoclonal Antibody Analysis of p53 Expression in Normal and Transformed Cells," J. Virol. 59, 1986, pp. 444-452 Yonish-Rouach, E. et al., "p53-Mediated Cell Death: Relationship to Cell Cycle Control," Mol. and Cell. Biol. 13, 1993, pp. 1415-1423 Yonish-Rouach, E. et al., "Wild-Type p53 Induces Apoptosis of Myeloid Leukaemic Cells that is Inhibited by Interleukin-6," Nature 352, 1991, pp. 345-347 Zambetti, G.P. et al., "Wild-Type p53 Mediates Positive Regulation of Gene Expression Through a Specific DNA Sequence Element," Genes & Dev. 6, 1992, pp. 1143-1152

*EXAMINER: Initial if reference conditions, whether or not citation is in conformance with MPEP 609; Draw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

DATE CONSIDERED